Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to 158976.92%.

  • Precision Biosciences' EBITDA Margin fell 1552833500.0% to 158976.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 12822.64%, marking a year-over-year decrease of 128010600.0%. This contributed to the annual value of 38.08% for FY2024, which is 516700.0% up from last year.
  • As of Q3 2025, Precision Biosciences' EBITDA Margin stood at 158976.92%, which was down 1552833500.0% from 121538.89% recorded in Q2 2025.
  • Precision Biosciences' 5-year EBITDA Margin high stood at 48.39% for Q2 2024, and its period low was 158976.92% during Q3 2025.
  • Its 5-year average for EBITDA Margin is 19333.07%, with a median of 199.32% in 2022.
  • As far as peak fluctuations go, Precision Biosciences' EBITDA Margin surged by 30748500bps in 2021, and later plummeted by -1552833500bps in 2025.
  • Precision Biosciences' EBITDA Margin (Quarter) stood at 484.68% in 2021, then skyrocketed by 76bps to 114.26% in 2022, then tumbled by -85bps to 211.57% in 2023, then crashed by -1741bps to 3894.36% in 2024, then plummeted by -3982bps to 158976.92% in 2025.
  • Its EBITDA Margin was 158976.92% in Q3 2025, compared to 121538.89% in Q2 2025 and 76248.28% in Q1 2025.